NCT07362108

Brief Summary

This retrospective cohort study evaluates cardiovascular events directly related to treated coronary arteries in patients with stable multivessel coronary artery disease. Outcomes in patients undergoing coronary artery bypass grafting or percutaneous coronary intervention will be compared with those receiving optimized medical therapy alone. This study aims to improve understanding of how different treatment strategies impact long-term vessel-related outcomes in patients with stable multivessel coronary artery disease.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,695

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 1995

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1995

Completed
31 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

January 15, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 23, 2026

Completed
Last Updated

January 23, 2026

Status Verified

January 1, 2026

Enrollment Period

31 years

First QC Date

January 15, 2026

Last Update Submit

January 15, 2026

Conditions

Stable Coronary Artery DiseaseMultivessel Coronary Artery DiseaseCoronary Artery DiseaseMyocardial Ischemia

Keywords

Coronary artery bypass graftingPercutaneous coronary interventionMedical therapyStable coronary artery diseaseMultivessel diseaseVessel-related outcomesMyocardial infarctionCardiac deathMASS study

Outcome Measures

Primary Outcomes (2)

  • Non-fatal myocardial infarction related to the treated coronary artery

    Up to 5 years of follow-up

  • Cardiac death attributable to the treated coronary artery

    Up to 5 years of follow-up

Study Arms (3)

Coronary Artery Bypass Grafting (CABG)

Patients with stable multivessel coronary artery disease treated with surgical coronary artery bypass grafting.

Procedure: Coronary Artery Bypass Grafting

Percutaneous Coronary Intervention (PCI)

Patients with stable multivessel coronary artery disease treated with percutaneous coronary intervention.

Procedure: Percutaneous Coronary Intervention

Medical Therapy

Patients with stable multivessel coronary artery disease treated exclusively with optimized medical therapy.

Other: Optimized Medical Therapy

Interventions

Coronary Artery Bypass GraftingPROCEDURE

Surgical myocardial revascularization using coronary artery bypass grafting.

Coronary Artery Bypass Grafting (CABG)
Optimized Medical TherapyOTHER

Guideline-directed medical therapy for stable coronary artery disease.

Medical Therapy
Percutaneous Coronary InterventionPROCEDURE

Percutaneous coronary intervention performed according to standard clinical practice.

Percutaneous Coronary Intervention (PCI)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients with stable multivessel coronary artery disease and documented myocardial ischemia, selected from the MASS (Medicine, Angioplasty, or Surgery Study) database at a single tertiary academic center.

You may qualify if:

  • Patients with stable multivessel coronary artery disease, defined as ≥70% stenosis in at least two major epicardial coronary arteries, with documented myocardial ischemia and clinical indication for surgical, percutaneous, or medical treatment.

You may not qualify if:

  • Patients with limited life expectancy, severe left ventricular dysfunction (ejection fraction \<35%), recent acute coronary syndrome, recent revascularization procedures, significant valvular disease, chronic kidney disease (creatinine ≥2.0 mg/dL), active malignancy, or inability to complete long-term follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Coronary Artery DiseaseMyocardial IschemiaMyocardial InfarctionDeath

Interventions

Coronary Artery BypassPercutaneous Coronary Intervention

Condition Hierarchy (Ancestors)

Coronary DiseaseHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

Myocardial RevascularizationCardiac Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeVascular GraftingVascular Surgical ProceduresThoracic Surgical ProceduresEndovascular ProceduresMinimally Invasive Surgical Procedures

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

January 15, 2026

First Posted

January 23, 2026

Study Start

January 1, 1995

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

January 23, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared publicly because this study is based on a retrospective institutional database with data ownership governed by institutional policies and local data protection regulations. De-identified data may be made available upon reasonable request, subject to approval by the investigators and the institutional ethics committee.